Publications by authors named "Masaaki Yuge"
Article Synopsis
- * Researchers conducted whole-exome sequencing on samples from 21 IVLBCL patients, revealing a significantly higher concentration of cell-free DNA (cfDNA) in IVLBCL compared to other types of lymphoma and healthy individuals, which helped in identifying key genetic mutations.
- * The study found that IVLBCL features a high frequency of mutations associated with activated B-cell-type diffuse large B-cell lymphoma and suggests that immune evasion plays a significant role in its development, highlighting potential therapeutic targets involving PD-1/PD-L1
Article Synopsis
- Intravascular large B-cell lymphoma (IVLBCL) is a rare type of cancer without standard treatments, prompting this study to explore the effectiveness of an experimental therapy combining R-CHOP and high-dose methotrexate with intrathecal chemotherapy.
- The PRIMEUR-IVL trial was conducted across 22 hospitals in Japan, involving 38 patients aged 20-79 years with untreated IVLBCL, focusing on their safety and potential response to the new treatment protocol over a planned follow-up.
- Initial findings show that 37 patients were eligible for the study, with a median follow-up period of around 3.9 years, indicating that the trial is still ongoing to evaluate long-term outcomes and effectiveness.
Introduction: The prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) has been dramatically improved since the introduction of tyrosine kinase inhibitors (TKIs). Although allogeneic hematopoietic cell transplantation (allo-HCT) is a major treatment option, the role of autologous peripheral blood stem cell transplantation (auto-PBSCT) has been reconsidered, especially in patients who achieved early molecular remission.
Methods And Analysis: This is a multicenter exploratory study for Ph + ALL patients aged between 55 and 70 years who achieved complete molecular remission within 3 cycles of chemotherapy.
A 40's year-old female patient with acute myeloblastic leukemia received high-dose cytarabine(HD-Ara-C)as her third induction therapy. Because the pharmacist in charge noticed on a prior interview that she had experienced a mild skin eruption similar to hand-foot syndrome(HFS)in the previous round oftherapy(idarubicin and cytarabine), heparinoid lotion and hypoallergenic soap were used to prevent HFS. However, HFS occurred on day 3, and further developed on day 6 to grade 3 with painful erythema, swelling, and paresthesia affecting the entire surface of both hands.
View Article and Find Full Text PDFTo evaluate the role of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in intravascular large B-cell lymphoma (IVLBCL), we retrospectively analyzed four consecutive IVLBCL patients receiving FDG-PET before treatment between May 2006 and November 2007. Patients were two men and two women (median age 62 years, range 54-76 years). All patients received bone marrow biopsies and random skin biopsies and two of the four patients underwent renal biopsy for diagnosis.
View Article and Find Full Text PDFThe cyclin-dependent kinase inhibitor p57(KIP2) is thought to be a potential tumor suppressor gene (TSG). The present study examines this possibility. We found that the expression of p57(KIP2) gene is absent in various hematological cell lines.
View Article and Find Full Text PDF